25C-NBOMe, also known as NBOMe-2C-C, 2C-C-NBOMe, or Cimbi-82, is a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. It acts as a potent agonist of the 5-HT<sub>2A</sub> receptor, and has been studied in its <sup>11</sup>C radiolabelled form as a potential ligand for mapping the distribution of 5-HT<sub>2A</sub> receptors in the brain, using positron emission tomography (PET). Multiple deaths have occurred from usage of 25C-NBOMe due to the ease of accidental overdose. The long-term toxic effects of the drug have not been researched. 25C-NBOMe was first described in the scientific literature by 2010.
25C-NBOMe is extremely potent and the effects of the drug increase greatly within a small window of dose adjustment. Overdose may occur at as little as double an average dose. With inaccurate dosing of street blotter paper, when mistaken for LSD, or when taken as a powder or liquid, this has resulted in multiple accidental deaths.
One study has shown that 25C-NBOMe blotters have 'hotspots' of the drug and the dose is not evenly applied over the surface of the paper, which could lead to overdose. Sublingually, the threshold for the onset of hallucinogenic effects reportedly is about 100âÂÂ250 üg, with mild effects at 250âÂÂ450, strong effects at 450âÂÂ800, and very strong effects over 800 üg.
NBOMe-substituted compounds have a diminished absorption rate passing through mucous membranes, but generally remain inactive when taken orally. Buccal, sublingual or insufflated routes of administration are all viable options. Absorption rate buccally and sublingually can be increased when complexed with HPBCD complexing sugar, however the most efficient is nasal administration, which shortens the duration while increasing intensity, but has been attributed to several overdoses and deaths.
25C-NBOMe acts as a serotonin 5-HT<sub>2</sub> receptor agonist, including of the serotonin 5-HT<sub>2A</sub> receptor.
25C-NBOMe has been found to produce neurotoxicity in rodents.
25C-NBOMe is derived from the psychedelic phenethylamine 2C-C by substitution on the amine with a 2-methoxybenzyl group. 25C-NBOMe is a clumpy white powder with a notably bitter and metallic taste.
Analogues of 25C-NBOMe include 2C-C, DOC, 25I-NBOMe, 25B-NBOMe, 25C-NBOH, 25C-NB3OMe, 25C-NB4OMe, and 25C-NBF, among others.
25C-NBOMe was first described in the scientific literature by Anders Ettrup and colleagues by 2010.
25C-NBOMe has been found on blotter mimics sold as LSD.
As of October 31, 2016; 25C-NBOMe is a controlled substance (Schedule III) in Canada.
As of October 2015, 25C-NBOMe is a controlled substance in China.
25C-NBOMe is banned in the Czech Republic.
The NBOMe series of psychoactives became controlled in Israel in May, 2013.
25C-NBOMe was sold as a designer drug in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen DOB, and was therefore a Class C controlled drug analogue.
Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.
Sveriges riksdag added 25C-NBOMe to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of Aug 1, 2013, published by Medical Products Agency in their regulation LVFS 2013:15 listed as 25C-NBOMe 2-(4-kloro-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin.
Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe. In November 2015, the temporary scheduling was extended for another year. Subsequently, they became permanently controlled.